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Abstract Primary open angle glaucoma (POAG) is a major
type of glaucoma characterized by progressive loss of retinal
ganglion cells with associated visual field loss without an iden-
tifiable secondary cause. Genetic factors are considered to be
major contributors to the pathogenesis of glaucoma. The aim of
the study was to identify the causative gene in a large family
with POAG by applying whole exome sequencing (WES).
WESwas performed on the DNA of four affected family mem-
bers. Rare pathogenic variants shared among the affected indi-
viduals were filtered. Polymerase chain reaction and Sanger
sequencing were used to analyze variants segregating with the
disease in additional family members. WES analysis identified
a variant in TP53BP2 (c.109G>A; p.Val37Met) that segregated
heterozygously with the disease. In silico analysis of the sub-
stitution predicted it to be pathogenic. The variant was absent in
public databases and in 180 population-matched controls. A
novel genetic variant in the TP53BP2 gene was identified in a
family with POAG. Interestingly, it has previously been dem-
onstrated that the gene regulates apoptosis in retinal ganglion
cells. This supports that the TP53BP2 variant may represent the
cause of POAG in this family. Additional screening of the gene
in patients with POAG from different populations is required to
confirm its involvement in the disease.
Keywords Primary open angle glaucoma .Whole exome
sequencing . TP53BP2
Introduction
Glaucoma is a leading cause of irreversible blindness world-
wide, affecting more than 60 million people around the world
[1]. Glaucoma comprises a group of heterogeneous optic neu-
ropathies, characterized by progressive optic nerve degenera-
tion. The diagnosis of glaucoma is usually late, since the loss of
vision often starts in the periphery and progression to the loss of
central vision is late. Due to this, glaucoma is also called a silent
thief of sight, with devastating consequences to the patient’s
quality of life. Glaucoma is classified into two main types:
primary and secondary glaucoma. Among primary glaucoma
subtypes, primary open angle glaucoma (POAG) represents the
major type of glaucoma affecting about 35 million people
worldwide and is characterized by a juvenile or adult onset.
Patients with POAG have characteristic glaucomatous optic
nerve damage with corresponding visual field defects and an
open anterior chamber angle at gonioscopy, but no other
(congenital) anomalies [2, 3]. One of the significant risk factors
for POAG is elevation of intraocular pressure (IOP). However,
POAG also occurs in patients without elevated IOP, and an
elevated IOP does not necessarily lead to POAG [4]. The grad-
ual loss of the retinal ganglion cells (RGCs) is a hallmark of the
disease along with the increased IOP, but the exact pathophys-
iological mechanisms of the disease are not fully understood.
Well-studied risk factors associated with POAG include age,
family history, gender, ethnicity, central corneal thickness, and
myopia. In addition, genetic factors play an important role in
the disease etiology.
To date, more than 15 loci have been identified for glauco-
ma, and the causative gene has been identified for 5 of these
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loci: GLC1A (MYOC/TIGR) [5, 6], GLC1E (OPTN) [7, 8],
GLC1F (ASB10) [9, 10], GLC1G (WDR36) [11], and
GLC1H (EFEMP1) [12, 13]. In addition, mutations in the
CYP1B1 [14] gene were identified in primary congenital, ju-
venile onset and adult onset POAG [15–17]. Finding the
genes that cause glaucoma is the first step in improving early
diagnosis and treatment of patients suffering from glaucoma.
However, only less than 10% of POAG cases have pathogenic
mutations in these disease-causing genes. It is therefore likely
that the hereditary aspect of many of the remaining cases of
POAG is either in the unidentified genes or due to the com-
bined effects of several single nucleotide polymorphisms
(SNPs). In recent years, several genome-wide association
studies (GWAS) have identified several SNPs at different loci
including CAV1/CAV2 [18], TMCO1 [19], CDKN2B-AS1
[20], CDC7-TGFBR3 [21], SIX1/SIX6 [22], GAS7, ATOH7,
TXNRD2, ATXN2, and FOXC1 [23], to be associated with
POAG, but they explain only a fraction of the disease herita-
bility. In addition, the mechanisms how the associated loci
influence the development of disease are often unclear.
Therefore, additional genetic studies are required to explain
the heritability, to gain a better understanding in the disease
etiology, and to define new targets for treatment.
The goal of the current study was to identify the genetic




A large family with eight individuals affected by POAG and
one unaffected individual was ascertained. Affected and unaf-
fected individuals were examined by an ophthalmologist at the
Radboud University Medical Center in Nijmegen, the
Netherlands. The study adhered to the principles of the
Declaration of Helsinki and was approved by the Institutional
Ethical Review Board of the Radboud University Medical
Center in Nijmegen, the Netherlands. Blood samples were
drawn from the family members, after obtaining written in-
formed consent. DNAwas extracted using standard methods.
Clinical characterization of the affected individuals includ-
ed slit-lamp examination for iris diaphany, funduscopy, and
IOP measurement with Goldmann applanation tonometry.
Assessment of visual field defects was performed with a
Humphrey Visual Field Analyzer (Carl Zeiss Humphrey
Systems, Dublin, CA, USA). The decisions about
glaucomatous damage on visual fields were based on the di-
agnostic criteria of the Hodapp et al. classification [24].
Evaluation of the anterior chamber angle was performed by
gonioscopy, and corneal thickness was calculated by ultra-
sound pachymetry. In addition, a morphometric analysis of
the optic disk was carried out by the Heidelberg Retina
Tomograph II (HRT II; Heidelberg Engineering, Heidelberg,
Germany), as described elsewhere [25]. An ophthalmic pho-
tographer masked to the results of the previous tests conducted
the examination. The HRT Moorfields regression analysis
(MRA) was used for classification of the optic disk [26].
The diagnosis of POAGwas made when the following criteria
were met: IOP higher than 22 mmHg (as measured by
applanation tonometry in both eyes), glaucomatous optic neu-
ropathy present in both eyes at funduscopy, visual field loss
consistent with assessed optic neuropathy in at least one eye,
and an open anterior chamber angle by gonioscopy.
Whole Exome Sequencing and Analysis
To identify the underlying genetic cause of the disease in this
large family with POAG,WES was performed using genomic
DNA of four affected individuals (III:1, III:5, III:6, and III:8)
(Fig. 1). Enrichment of exonic sequences was achieved by
using the SureSelectXT Human All Exon V.2 Kit (50 Mb)
(Agilent Technologies, Inc., Santa Clara, CA, USA).
Sequencing was performed on a SOLiD 4 sequencing plat-
form (Life Technologies, Carlsbad, CA, USA). The hg19 ref-
erence genome was aligned with the reads obtained using
SOLiD LifeScope software V.2.1 (Life Technologies).
To identify the causative variant, only the variants shared
by the four affected individuals were included for further anal-
ysis. All variants present within intergenic, intronic, and un-
translated regions and synonymous substitutions were exclud-
ed. Variants present in the public genetic variant databases,
including the Exome Variant Server (http://evs.gs.
washington.edu/EVS/), dbSNP132 (http://www.ncbi.nlm.
nih.gov/projects/SNP/snp_summary.cgi?build_id=132), and
1000 Genomes (http://www.1000genomes.org/) with an
allele frequency >0.5%, were excluded.
To evaluate the pathogenicity of the variants obtained from
WES, bioinformatic analysis was performed using the PhyloP
(nucleotide conservation in various species) and Grantham
scores (difference in physicochemical nature of amino acid
substitutions). Functional predictions were performed using
publically available tools, i.e., SIFT (http://sift.bii.a-star.
edu.sg/ Sorting Intolerant from Tolerant), MutationTaster
(http:/ /www.mutationtaster.org/), and PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/ Polymorphism
Phenotyping). Confirmation of variants and segregation
analysis in all available family members was performed
using PCR and Sanger sequencing. Sequencing was
performed using the Big Dye Terminator Cycle Sequencing-
Ready Reaction Kit (Applied Biosystems) on a 3730 DNA
automated sequencer (Applied Biosystems, Foster City, CA,
USA) using standard protocols. Segregating variants were an-




Microsatellite markers with a genetic heterogeneity >60%
were selected from the UCSC database. Microsatellite
markers D1S2655, D1S2891, D1S2629, and D1S229 were
amplified with M13 tailed primers, followed by a second
PCRwith fluorescently labeledM13 primers. Fluorescent am-
plification products were visualized on the ABI-310 genetic
analyzer, and the size of the alleles was determined with
500LIZ (Applied Biosystems, Bleiswijk, the Netherlands)
and analyzed with the GeneMapper software version 3.7
(Applied Biosystems, Bleiswijk, the Netherlands).
Multipoint linkage analysis was performed for informative
markers to determine the logarithm of the odds (LOD) score
using the GeneHunter program (version 2.1).11 in the
easyLINKAGE Software package (http://nephrologie.
uniklinikum-leipzig.de/nephrologie.site,postext,easylinkage,a_
id,797.html). For linkage analysis, autosomal dominant
inheritance was assumed, with a disease-allele frequency of
0.0001 and 95% penetrance.
Results
Clinical Evaluation
Table 1 provides detailed clinical information of the eight
affected family members diagnosed with POAG. All individ-
uals had open drainage angles on gonioscopy (at least Shaffer
grade III) and normal results of corneal thickness evaluation.
Themean age at diagnosis was 54.8 years (range 49–60 years),
with a mean IOP of 13.2 ± 2.2 mmHg (after use of IOP low-
ering medications). All individuals had bilateral glaucoma:
they had glaucomatous optic neuropathy on funduscopy with
reproducible compatible glaucomatous visual field loss, and
all individuals showed abnormal results on Heidelberg Retina
Tomograph II testing. A representative color photo of the optic
disk of individual III-9 with POAG, with the corresponding
superior arcuate scotoma on Humphrey visual field testing
is shown in Fig. 2. From the medical chart, we distilled that
the mean highest IOP recorded on diurnal testing was
23.6 ± 4.7 mmHg.
Mutation Detection
In Table 2, the number of variants that passed the various
filtering steps per individual for the four affected individuals,
as well as the variants shared by all four affected individuals is
shown. The mean coverage of the WES data was 100X.
Filtering for variants shared between all four affected individ-
uals (III:1, III:5, III:6, and III:8) resulted in nine variants for
further analysis (Table 3). Segregation analysis was performed
for nine variants with a phyloP >2.7 or a Grantham score >80
(Table 3). Two novel heterozygous variants in the TP53BP2
andMAPKAPK2 genes were found to be segregating with the
disease in the family (Fig. 1). The variant in the TP53BP2
gene (c.109G>A; p.Val37Met) was predicted to be deleterious
by SIFT, probably damaging by PolyPhen-2 and disease-
Fig. 1 Pedigree of a family with individuals affected by POAG. The
(c.109G>A; p.Val37Met) variant in the TP53BP2 gene is indicated with
M2, the variant (c.305G >A; p.Arg102His) in the MAPKAPK2 gene is
indicated with M1, and the wild type allele is indicated with WT for both
genes together with microsatellite markers haplotype. All affected
individuals carry both variants heterozygously, while the unaffected












































































































































































































































































































































































































































































































































































































































































































































































































































































































causing by Mutation Taster (Table 3). The wild type nucleo-
tide was highly conserved (phyloP score 4.08), and the amino
acid residue p.Val37 was completely conserved among verte-
brates (Fig. 3a). The second variant that segregated with the
disease in the family was identified in the MAPKAPK2 gene
(c.305G>A; p.Arg102His) (Fig. 1). This variant was also pre-
dicted to be deleterious by SIFT, probably damaging by
PolyPhen and disease-causing by Mutation Taster (Table 3).
The wild type nucleotide was highly conserved (phyloP score
5.69), and the amino acid residue p.Arg102 is completely
conserved among vertebrates (Fig. 3b). Both variants were
not identified in 180 population-matched controls and were
not present in the Exome Variant Server, dbSNP132 and 1000
genomes.
Linkage Analysis
Twelve microsatellite markers were used for linkage analysis
of the genomic region encompassing the MAPKAPK2 and
TP53BP2 genes, but only four markers were informative. A
multipoint LOD score of 2.48 was obtained for markers
D1S2655 and D1S2891, which is suggestive of linkage and
is in accordance with the maximum LOD score that can be
achieved considering the structure of the pedigree. The
disease-associated haplotype encompasses markers
D1S2655, the MAPKAPK2 variant, D1S2891, D1S2629,
D1S229, and the TP53BP2 variant. All affected individuals
carry the disease haplotype that includes both genetic variants,
which indicates that both variants are in the same linkage
interval and are in cis configuration.
Discussion
In the current study, we used WES to identify the genetic
defect in a large family with POAG. We identified potentially
pathogenic variants in the TP53BP2 (c.109G>A; p.Val37Met)
andMAPKAPK2 (c.305G>A; p.Arg102His) genes. A disease
haplotype carrying both variants segregates with the disease,
with a maximum LOD score of 2.4. Variants in both TP53BP2
and MAPKAPK2 segregate with the disease, since both of
them are on the same haplotype. Therefore, segregation of
the MAPKAPK2 variant with the disease is a coincidental
finding. Since the inheritance pattern was not obvious from
the pedigree, we considered both recessive and dominant in-
heritance patterns during the variant prioritization process.
However, no homozygous or compound heterozygous vari-
ants were identified among the putative pathogenic variants
that were shared between affected individuals, and this thus
does not support recessive inheritance. Since phenotype data
and DNA were not available from the deceased parents, we
can only speculate that the inheritance pattern may be autoso-
mal dominant.
Fig. 2 Photograph of the optic
disk (a) and Humphrey visual
field testing (b) of the left eye in a
76-years-old patient (III-9) with
POAG and a corresponding
visual acuity of 20/32. a
Photograph shows a pallor,
glaucomatous excavated optic
disk. b Visual field testing shows
a superior arcuate scotoma as well
as inferior defects that are
congruent with the excavation of
the optic disk
Table 2 Number of variants identified per individual and shared between four affected individuals
Filtration steps Individual 1 Individual 2 Individual 3 Individual 4 Variants shared
by all 4 individuals
Total number of variants 45.755 47.697 45.417 41.943 21.447
SNP frequency <0.5 28.789 30.381 28.614 26.252 9.065
In-house database frequency <0.5 2.152 2.529 2.503 2.373 55
Exonic and canonical splice site variants 796 873 961 987 33
Nonsynonmous variants 535 620 682 696 18
Grantham score >80 248 268 302 323 4
Phylop >2.7 22 31 24 22 9
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TP53BP2 encodes a member of the ASPP (apoptosis-
stimulating protein of p53) family of p53-interacting proteins
comprised of three members: ASPP1, ASPP2, and iASPP.
Both ASPP1 and ASPP2 are proapoptotic proteins involved
in the regulation of the apoptosis and are encoded by the
TP53BP2, and iASPP is encoded by PPP1R13B genes,
Table 3 Rare variants shared by four affected individuals and segregation analysis






SIFT Mutation Taster PolyPhen-2
TP53BP2 NM_001031685 109C>T p.Val37Met 4.135 Yes 21 Deleterious Disease causing Probably damaging
MAPKAPK2 NM_032960 305G>A p.Arg102His 5.691 Yes 29 Deleterious Disease causing Probably damaging
TGFBI NM_000358 895G>A p.Asp299Asn 5.884 No 23 Tolerated Disease causing Probably damaging
ADSSL1 NM_199165 578C>T p.Ser193Phe 5.657 No 155 Deleterious Disease causing Probably damaging
NCEH1 NM_001146276 142C>T p.Ala48Thr 5.305 No 58 Tolerated Disease causing Probably damaging
RNF157 NM_052916 1913C>G p.Cys638Ser 5.254 No 112 Tolerated Disease causing Probably damaging
PHC3 NM_024947 1840C>T p.Glu614Lys 3.961 No 56 Tolerated Disease causing Possibly damaging
SLITRK3 NM_014926 2581G>A p.Arg861Cys 3.886 No 180 Deleterious Disease causing Possibly damaging
RYR2 NM_001035 8162 T>C p.Ile2721Thr 3.683 No 89 Deleterious Disease causing Possibly damaging
Fig. 3 a Evolutionary
conservation of valine at position
37 is represented by alignment of
the human TP53BP2 (ASPP2)
protein sequence to orthologous
protein sequences of various
vertebrate species. b Evolutionary
conservation of arginine at
position 102 is represented by
alignment of the human
MAPKAPK2 protein sequence to
orthologous protein sequences of
various vertebrate species
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respectively [27]. ASPP2 is well known for its binding and
activation of the apoptotic function of p53, p63, and p73 by
selectively enhancing their DNA-binding and transactivation
activities on proapoptotic genes such as BAX and PIG3 [27,
28]. Apoptosis is tightly regulated during normal develop-
ment. In the case of abnormal regulation, it mediates cell death
of neuronal cells in neurodegenerative diseases such as
Alzheimer’s disease or Parkinson’s disease or death of
RGCs in glaucoma due to overexpression of p53 [29–31].
Recently, the role of ASPP1 and ASPP2 proteins in neuronal
apoptosis and their involvement in the regulation of adult
RGCs after injury have been investigated. The results indicat-
ed that both ASPP1 and ASPP2 are highly expressed in RGCs
and contribute to p53-dependent death of RGCs.
In glaucoma cell death of the post-mitotic neurons, i.e.,
RGCs, occurs due to an increased rate of apoptosis. The
ASPP proteins are involved in the regulation of apoptosis
by activating p53. The expression of ASPP2 affects the
DNA binding activity of p53 on the Bax promoter or down-
stream targets involved in apoptosis [32]. In the current study,
we speculate that binding between ASPP2 and p53 may be
affected by an amino acid variant (c.109G>A; p.Val37Met) in
the ASPP2 protein, which leads to the increased accumula-
tion of p53, followed by an increase in cell death of the
RGCs, subsequently leading to glaucoma. Previously, it has
been reported that normal ASSP2 protein is required for the
activation of apoptosis in a controlled manner. It was ob-
served that the blockade of the ASPP-p53 pathway is impor-
tant for the survival of neurons after axonal injury [33]. The
results of Wilson et al. are further supported by a recent study
in an in vivo model of acute optic nerve damage, in which it
was shown that iASPP is expressed by injured RGCs and
short interference RNA (siRNA)-induced iASPP knockdown
exacerbates RGC death, while RGC survival was enhanced
by adeno-associated virus (AAV)-mediated iASPP expres-
sion. Increased expression of iASPP in RGCs downregulates
p53 activity and blocks the expression of proapoptotic targets
PUMA and Fas/CD95 [34]. Since iASPP is an inhibitor of
p53-mediated apoptosis, it is possible that the mutation in the
ASPP2 protein influences the expression of iASPP.
Subsequently, it would not be able to perform actively in
the survival of retinal ganglion cells due to apoptosis.
In a recent study, it has been observed that siRNA interfer-
ing the expression of ASPP2 is involved in the development
of the proliferative vitreoretinopathy (PVR). Using epiretinal
membranes of PVR patients, they examined the expression of
ASPP2 using immunohistochemistry and observed reduced
expression of ASPP2 in PVRmembranes. In addition, knock-
down of ASPP2 is involved in increased expression of cyto-
kines such as TGF-β, CTGF, VEGF, TNF-α, and interleukins
[35]. In glaucoma, the role of inflammatory cytokines is well
known, and it is possible that the amino acid variant identified
in the ASPP2 protein affects the expression of inflammatory
cytokines and interleukins, which mediate apoptosis of retinal
ganglion cells in glaucoma. In another recent study, the neu-
roprotective effect of minocycline in rats with glaucoma was
evaluated, and downregulation of TP53BP2was observed up-
on treatment [36]. Minocycline is a tetracycline with anti-
inflammatory and anti-apoptotic properties. In previous stud-
ies, it has been shown that minocycline significantly delays
RGC death in models of experimental glaucoma and optic
nerve transaction [37].
Taken together, these studies support the involvement of
the TP53BP2 gene in glaucoma and suggest that the genetic
variant identified by WES in the large POAG family may be
relevant to the disease.
The second variant that segregates with the disease in the
family was identified in MAPK-activated protein kinase 2
(MAPKAPK2, also known as MK2), which is one of the
downstream targets of p38 MAPK. The Ocular Tissue
Database (OTDB, http://genome.uiowa.edu/otdb/)
demonstrates a minimal expression in the eye for
MAPKAPK2 in contrast to TP53BP2. Therefore, TP53BP2
gene seems to be the strongest candidate to be associated with
the disease in this particular family.
In conclusion, through WES in a large POAG family, we
identified a novel genetic variant in the TP53BP2 gene, which
is predicted to be pathogenic and affects a highly conserved
amino acid residue. Since it has been demonstrated that the
gene regulates apoptosis in RGCs and is downregulated upon
minocycline treatment in a glaucoma rat model, TP53BP2
may represent a novel gene associated with POAG.
Additional screening of the TP53BP2 gene in other familial
and sporadic patients with POAG from different populations
is required to confirm its involvement in the disease.
Acknowledgements This study was supported by the Stichting
Blindenhulp, a Shaffer grant from the Glaucoma Research Foundation
and the following foundations: Glaucoomfonds, Oogfonds, and
Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, which
contributed through UitZicht.
Compliance with Ethical Standards The study adhered to the princi-
ples of the Declaration of Helsinki and was approved by the Institutional
Ethical Review Board of the Radboud University Medical Center in
Nijmegen, the Netherlands.
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
Mol Neurobiol
References
1. Quigley HA, Broman AT (2006) The number of people with glau-
coma worldwide in 2010 and 2020. Br J Ophthalmol 90(3):262–
267. doi:10.1136/bjo.2005.081224
2. Hitchings RA (1992) Low tension glaucoma—its place in modern
glaucoma practice. Br J Ophthalmol 76(8):494–496
3. Grosskreutz C, Netland PA (1994) Low-tension glaucoma. Int
Ophthalmol Clin 34(3):173–185
4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL,
Miller JP, Parrish RK 2nd, Wilson MR et al (2002) The Ocular
Hypertension Treatment Study: a randomized trial determines that
topical ocular hypotensive medication delays or prevents the onset
of primary open-angle glaucoma. Arch Ophthalmol 120(6):701–
713 discussion 829-730
5. Sheffield VC, Stone EM, Alward WL, Drack AV, Johnson AT,
Streb LM, Nichols BE (1993) Genetic linkage of familial open
angle glaucoma to chromosome 1q21-q31. Nat Genet 4(1):47–50.
doi:10.1038/ng0593-47
6. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR,
Sunden SL, Nishimura D, Clark AF et al (1997) Identification of
a gene that causes primary open angle glaucoma. Science
275(5300):668–670
7. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M,
Heon E, Krupin T et al (2002) Adult-onset primary open-angle
glaucoma caused by mutations in optineurin. Science 295(5557):
1077–1079. doi:10.1126/science.1066901
8. Sarfarazi M, Child A, Stoilova D, Brice G, Desai T, Trifan OC,
Poinoosawmy D, Crick RP (1998) Localization of the fourth locus
(GLC1E) for adult-onset primary open-angle glaucoma to the 10p15-
p14 region. Am J Hum Genet 62(3):641–652. doi:10.1086/301767
9. WirtzMK, Samples JR, Rust K, Lie J, Nordling L, Schilling K, Acott
TS, Kramer PL (1999) GLC1F, a new primary open-angle glaucoma
locus, maps to 7q35-q36. Arch Ophthalmol 117(2):237–241
10. Pasutto F, Keller KE,WeisschuhN, Sticht H, Samples JR, Yang YF,
Zenkel M, Schlotzer-Schrehardt U et al (2012) Variants in ASB10
are associated with open-angle glaucoma. Hum Mol Genet 21(6):
1336–1349. doi:10.1093/hmg/ddr572
11. Monemi S, Spaeth G, DaSilva A, Popinchalk S, Ilitchev E,
Liebmann J, Ritch R, Heon E et al (2005) Identification of a novel
adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1.
Hum Mol Genet 14(6):725–733. doi:10.1093/hmg/ddi068
12. Suriyapperuma SP, Child A, Desai T, Brice G, Kerr A, Crick RP,
Sarfarazi M (2007) A new locus (GLC1H) for adult-onset primary
open-angle glaucoma maps to the 2p15-p16 region. Arch
Ophthalmol 125(1):86–92. doi:10.1001/archopht.125.1.86
13. Mackay DS, Bennett TM, Shiels A (2015) Exome sequencing iden-
tifies a missense variant in EFEMP1 co-segregating in a family with
autosomal dominant primary open-angle glaucoma. PLoS One
10(7):e0132529. doi:10.1371/journal.pone.0132529
14. Sarfarazi M, Akarsu AN, Hossain A, Turacli ME, Aktan SG,
Barsoum-Homsy M, Chevrette L, Sayli BS (1995) Assignment of
a locus (GLC3A) for primary congenital glaucoma (buphthalmos)
to 2p21 and evidence for genetic heterogeneity. Genomics 30(2):
171–177
15. Stoilov I, Akarsu AN, Sarfarazi M (1997) Identification of three
different truncating mutations in cytochrome P4501B1 (CYP1B1)
as the principal cause of primary congenital glaucoma
(buphthalmos) in families linked to the GLC3A locus on chromo-
some 2p21. Hum Mol Genet 6(4):641–647
16. Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, Trope G,
Williams-Lyn D, Heon E (2002) Digenic inheritance of early-onset
glaucoma: CYP1B1, a potential modifier gene. Am J Hum Genet
70(2):448–460. doi:10.1086/338709
17. Melki R, Colomb E, Lefort N, Brezin AP, Garchon HJ (2004)
CYP1B1 mutations in French patients with early-onset primary
open-angle glaucoma. J Med Genet 41(9) :647–651.
doi:10.1136/jmg.2004.020024
18. Wiggs JL, Kang JH, Yaspan BL, Mirel DB, Laurie C, Crenshaw A,
Brodeur W, Gogarten S et al (2011) Common variants near CAV1
and CAV2 are associated with primary open-angle glaucoma in
Caucasians from the USA. Hum Mol Genet 20(23):4707–4713.
doi:10.1093/hmg/ddr382
19. Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G,Mills
RA, Danoy P, Casson R et al (2011) Genome-wide association
study identifies susceptibility loci for open angle glaucoma at
TMCO1 and CDKN2B-AS1. Nat Genet 43(6):574–578.
doi:10.1038/ng.824
20. Pasquale LR, Loomis SJ, Kang JH, Yaspan BL, Abdrabou W,
Budenz DL, Chen TC, Delbono E et al (2013) CDKN2B-AS1
genotype-glaucoma feature correlations in primary open-angle
glaucoma patients from the United States. Am J Ophthalmol
155(2):342–353. doi:10.1016/j.ajo.2012.07.023
21. Li Z, Allingham RR, Nakano M, Jia L, Chen Y, Ikeda Y, Mani B,
Chen LJ et al (2015) A common variant near TGFBR3 is associated
with primary open angle glaucoma. HumMol Genet 24(13):3880–
3892. doi:10.1093/hmg/ddv128
22. Wiggs JL, Yaspan BL, Hauser MA, Kang JH, Allingham RR,
Olson LM, Abdrabou W, Fan BJ et al (2012) Common variants at
9p21 and 8q22 are associated with increased susceptibility to optic
nerve degeneration in glaucoma. PLoS Genet 8(4):e1002654.
doi:10.1371/journal.pgen.1002654
23. Bailey JN, Loomis SJ, Kang JH, Allingham RR, Gharahkhani P,
Khor CC, Burdon KP, Aschard H et al (2016) Genome-wide asso-
ciation analysis identifies TXNRD2, ATXN2 and FOXC1 as sus-
ceptibility loci for primary open-angle glaucoma. Nat Genet 48(2):
189–194. doi:10.1038/ng.3482
24. Hodapp E PRI, Anderson DR. (1993) Clinical decisions in glauco-
ma. The CV Mosby Co;, St Louis
25. Mikelberg FS, Parfitt CM, Swindale NV, Graham SL, Drance SM,
Gosine R (1995) Ability of the Heidelberg Retina Tomograph to
detect early glaucomatous visual field loss. J Glaucoma 4(4):242–
247
26. Wollstein G, Garway-Heath DF, Hitchings RA (1998)
Identification of early glaucoma cases with the scanning laser
ophthalmoscope. Ophthalmology 105(8):1557–1563.
doi:10.1016/S0161-6420(98)98047-2
27. Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh
JK, Zhong S, Campargue I, Naumovski L et al (2001) ASPP pro-
teins specifically stimulate the apoptotic function of p53. Mol Cell
8(4):781–794
28. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X
(2004) ASPP1 and ASPP2: common activators of p53 family mem-
bers. Mol Cell Biol 24(3):1341–1350
29. ChatooW, AbdouhM, Bernier G (2011) p53 pro-oxidant activity in
the central nervous system: implication in aging and neurodegener-
ative diseases. Antioxid Redox Signal 15(6):1729–1737.
doi:10.1089/ars.2010.3610
30. Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis.
Biochem Biophys Res Commun 331(3):761–777. doi:10.1016/j.
bbrc.2005.03.149
31. Nickells RW (1999) Apoptosis of retinal ganglion cells in glauco-
ma: an update of the molecular pathways involved in cell death.
Surv Ophthalmol 43:151–161
32. Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh
JK, Zhong S, Campargue I, Naumovski L et al (2001) ASPP pro-
teins specifically stimulate the apoptotic function of p53. Mol Cell
8(4):781–794. doi:10.1016/S1097-2765(01)00367-7
33. Wilson AM, Morquette B, Abdouh M, Unsain N, Barker PA,
Feinstein E, Bernier G, Di Polo A (2013) ASPP1/2 regulate p53-
Mol Neurobiol
dependent death of retinal ganglion cells through PUMA and Fas/
CD95 activation in vivo. The Journal of neuroscience : the official
journal of the Society for Neuroscience 33(5):2205–2216.
doi:10.1523/JNEUROSCI.2635-12.2013
34. Wilson AM, Chiodo VA, Boye SL, Brecha NC, HauswirthWW, Di
Polo A (2014) Inhibitor of apoptosis-stimulating protein of p53
(iASPP) is required for neuronal survival after axonal injury.
PLoS One 9(4):e94175. doi:10.1371/journal.pone.0094175
35. Chen XL, Bai YJ, Hu QR, Li SS, Huang LZ, Li XX (2016) Small
interfering RNA targeted to ASPP2 promotes progression of exper-
imental proliferative vitreoretinopathy. Mediat Inflamm.
doi:10.1155/2016/7920631
36. Levkovitch-Verbin H, Waserzoog Y, Vander S, Makarovsky D,
Piven I (2014) Minocycline upregulates pro-survival genes and
downregulates pro-apoptotic genes in experimental glaucoma.
Graefe’s archive for clinical and experimental ophthalmology
Albrecht von Graefes Archiv fur klinische und experimentelle
Ophthalmologie 252(5):761–772. doi:10.1007/s00417-014-2588-4
37. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed
S (2006) Minocycline delays death of retinal ganglion cells in exper-
imental glaucoma and after optic nerve transection. ArchOphthalmol
124(4):520–526. doi:10.1001/archopht.124.4.520
Mol Neurobiol
